Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US BioPharma Player Makes Neulasta Biosimilars Claim

Multiple Pegfilgrastim Rivals Are Competing In The US Market

Executive Summary

The US biosimilar market for Neulasta, one of the few ‘maturing’ markets with multiple biosimilar entrants, suggests that commercial strategy more than price is of greater importance as sponsors look to prize market share from Amgen – reflecting the chasm between certain biosimilar and traditional generic markets.

You may also be interested in...

Coherus Will Prioritize Oncology As Inflammation Takes A Back Seat

Coherus BioSciences enjoyed another strong quarter, “exceeding expectations,” management said, as the US-based player revealed where it would invest its cash pile following a round of financing in April.

Coherus BioSciences Outlines ‘Very Different Approach’ And Raises Another US$75m To Launch Udenyca

Just days after it began selling the second biosimilar pegfilgrastim product in the US, and the company’s first, Coherus BioSciences’ management took to the J.P. Morgan Healthcare Conference to explain how the company is set apart from rival Mylan. Through debt financing, the California-based player has also just grabbed a further US$75 million to fuel the biosimilar’s launch.

Pfizer Faces 15-Year Wait On US Adrenalin Generic

Pfizer’s efforts to circumvent two US patents shielding Par’s Adrenalin (epinephrine) have again ended in failure, following a ruling by the US Court of Appeals for the Federal Circuit.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts